EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Methylation synthetic lethality: Exploiting selective drug targets for cancer therapy

Bing-Jie Ye, Di-Fei Li, Xin-Yun Li, Jia-Lin Hao, Di-Jie Liu, Hang Yu, Chun-Dong Zhang

Cancer Letters · 2024-08 · 597 · 217010

DOI: 10.1016/j.canlet.2024.217010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Letters, 2024-08. Verfasst von Bing-Jie Ye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China. Hauptthemen laut MEDLINE: Neoplasms, DNA Methylation, Synthetic Lethal Mutations, Epigenesis, Genetic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 139 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In cancer, synthetic lethality refers to the drug-induced inactivation of one gene and the inhibition of another in cancer cells by a drug, resulting in the death of only cancer cells; however, this effect is not present in normal cells, leading to targeted killing of cancer cells. Recent intensive epigenetic research has revealed that aberrant epigenetic changes are more frequently observed than gene mutations in certain cancers. Recently, numerous studies have reported various methylation synthetic lethal combinations involving DNA damage repair genes, metabolic pathway genes, and paralogs with significant results in cellular models, some of which have already entered clinical trials with promising results. This review systematically introduces the advantages of methylation synthetic lethality and describes the lethal mechanisms of methylation synthetic lethal combinations that have recently demonstrated success in cellular models. Furthermore, we discuss the future opportunities and challenges of methylation synthetic lethality in targeted anticancer therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsDNA MethylationSynthetic Lethal MutationsEpigenesis, GeneticHumansAntineoplastic AgentsMolecular Targeted TherapyDNA RepairAnimals

Stichwörter der Autor:innen

EpigeneticsMethylationSynthetic lethality

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Clinical Medicine, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
  • Central Laboratory, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
  • Department of Surgical Oncology, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China.
  • Central Laboratory, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China; Department of Surgical Oncology, The Fourth Affiliated Hospital of China Medical University, Shenyang 110032, China…

Zitieren

APA

Ye, B. J., Li, D. F., Li, X. Y., Hao, J. L., Liu, D. J., Yu, H., & Zhang, C. D. (2024). Methylation synthetic lethality: Exploiting selective drug targets for cancer therapy. Cancer Letters, 597, 217010. https://doi.org/10.1016/j.canlet.2024.217010

Vancouver

Ye BJ, Li DF, Li XY, Hao JL, Liu DJ, Yu H, et al. Methylation synthetic lethality: Exploiting selective drug targets for cancer therapy. Cancer Letters. 2024;597:217010. doi:10.1016/j.canlet.2024.217010

BibTeX
@article{Ye2024,
  author = {Ye, Bing-Jie and Li, Di-Fei and Li, Xin-Yun and Hao, Jia-Lin and Liu, Di-Jie and Yu, Hang and Zhang, Chun-Dong},
  title = {Methylation synthetic lethality: Exploiting selective drug targets for cancer therapy},
  journal = {Cancer Letters},
  year = {2024},
  volume = {597},
  pages = {217010},
  doi = {10.1016/j.canlet.2024.217010}
}
Kostenlos starten →